Humacyte HUMA
NASDAQ HUMA
$0.52 -0.02 (-3.10%)
As of: Sep 30, 2026 · 2:52 PM EDT

Humacyte (HUMA) EBITDA Margin (2020 - 2026)

Updated

Humacyte's EBITDA Margin was -6319.95% in Q2 2026, up 3124.24 percentage points from -9444.19% a year earlier but down 745.61 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) EBITDA Margin (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Humacyte's EBITDA Margin was -4990.57% through Jun 30, 2026, up 7974.83 percentage points year-over-year; for FY2025, it was -5044.60%.

  • Quarterly EBITDA Margin has moved between -9444.19% (Q2 2025) and -3066.40% (Q3 2025) over five years.
  • Per Business Quant data, HUMA's EBITDA Margin in the three quarters before Q2 2026 was -5574.34% (Q1 2026), -6318.63% (Q4 2025) and -3066.40% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 Humacyte 147.23 Mn 147.23 Mn -825,000.00 -6,319.95%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6,319.95%
Mar 31, 2026 -5,574.34%
Dec 31, 2025 -6,318.63%
Sep 30, 2025 -3,066.40%
Jun 30, 2025 -9,444.19%
Mar 31, 2025 -4,234.43%
Sep 30, 2021 -7,901.66%
Sep 30, 2020 -1,708.21%
API Access

Humacyte EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY